NCT01757613已完成2 期
Three-armed, Randomized, Double-blind Dose-finding Trial on Efficiency and Safety of AK 3012 in 3 Different Concentrations in Patients With Actinic Keratosis Olsen Grade I/II
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 主要终点
- Change of skin alterations during treatment period
研究概览
简要总结
In this three-armed dose-finding trial 3 AK 3012 topical formulations shall be investigated with respect to safety and efficacy in order to identify the optimal concentration in the topical formulation.
The main objective of the trial is to determine the optimal concentration of the active agent in the topical formulation as quantified by the change of the number of skin alterations in pre-defined areas in a time period from inclusion in the trial until the end of treatment (3 months) or prior complete healing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: ≥ 18 years
- •Gender: male and female
- •Actinic Keratosis (Olsen grade I/II)
- •at least 5 actinic keratoses on the scalp, forehead, face, extremities, and/ or decollete
- •no treatment of the actinic keratoses within the previous 3 months before inclusion in the study
- •histologic confirmation of the diagnosis actinic keratosis by biopsy
- •good general condition
- •normal laboratory values (creatinine, urea, Glutamate-Oxalacetate Transaminase (GOT),Glutamate-Pyruvate Transaminase (GPT), gamma-glutamyl transferase (GGT), Lactate dehydrogenase (LDH)) and blood count at study start not higher than 1.5 x upper norm limit
- •Female patients must be tested negative for pregnancy before inclusion in the trial. During the trial, female patients have to apply a generally accepted form of birth control (i.e. oral estrogen- and gestagen containing contraceptives; estrogen containing skin plaster/ tape, hormone implant, hormone contraceptive coil, sterilisation; sexual abstinence) or being post-menopausal for at least 2 years.
- •Willing and able to participate in the screening and all trial specific procedures in compliance with the protocol
- •Signed written informed consent
排除标准
- •Known allergy against nonsteroidal antiphlogistics and/ or against excipients of the investigational medicinal product
- •Presence of immunosuppression
- •Treatment with 5-fluorouracil, cyclosporine, retinoids, glycolic acid, imiquimod, trichloroacetic acid during the trial or 12 weeks before inclusion in the trial
- •Continuous treatment with nonsteroidal antiphlogistics with the exception of low-dose acetylsalicylic acid (100 mg) for inhibition of thrombocyte aggregation
- •Planned treatment with photodynamic therapy during participation in the trial
- •Pregnancy or lactation
- •Participation in another clinical trial within 3 months before inclusion in the current trial
研究组 & 干预措施
AK 3012 a for topical use
Active Comparator
干预措施: AK 3012 (Drug)
AK 3012 b for topical use
Active Comparator
干预措施: AK 3012 (Drug)
AK 3012 c for topical use
Active Comparator
干预措施: AK 3012 (Drug)
结局指标
主要结局
Change of skin alterations during treatment period
时间窗: 90 days: Between Visit 0 (day 0) and Visit 3 (day 90)
次要结局
- Adverse events(90 days: Between Visit 0 (day 0) and Visit 3 (day 90))
- Tolerability of the investigated medicinal product(90 days: Between Visit 0 (day 0) and Visit 3 (day 90))
- Change of visible skin alterations during treatment period(90 days: Between Visit 0 (day 0) and Visit 3 (day 90))
研究者
相似试验
终止
不适用
Trial Evaluating Ambulatory Treatment of Travelers' DiarrheaAcute Watery DiarrheaDysentery/Febrile DiarrheaNCT01618591Uniformed Services University of the Health Sciences384
终止
2 期
Maintaining Suppression of Testosterone With Transdermal Estradiol GelCancer of the ProstateNCT02349386BHR Pharma, LLC34
已完成
2 期
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected IndividualsHIV InfectionsNCT00034866Boehringer Ingelheim165
终止
2 期
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureDiabetes Mellitus and Heart FailureNCT03152552Novartis Pharmaceuticals125
已完成
2 期
Safety Study of Anti-IgE Immunotherapy in Allergic PatientsAllergyNCT00439621Resistentia Pharmaceuticals AB42